4basebio
Miltiades Stylianou is an experienced professional in the field of manufacturing science and cellular biology. Currently serving as a Manufacturing Scientist level 4 at 4basebio since February 2022 and as a Scientist at TCR² Therapeutics Inc. since July 2021, Miltiades also works as a Scientist for the Medicines and Healthcare products Regulatory Agency since December 2016, overseeing the supply and distribution of quality assured cell banks and performing quality control testing in compliance with ISO standards. Previous roles include Cell Services and Panel Screening Protocol Manager at hVIVO, where operational planning for laboratory assays was managed, and Lab Manager for Cell Culture Services, ensuring adherence to GCP guidelines. Earlier experience includes serving as a Senior Biology Technician at Sodexo, providing crucial laboratory support for GSK scientists in mammalian cell culture and other related activities.
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.